新股消息 | 传干细胞疗法开发企业Pollon Life秘密申请香港上市 募资约3亿美元

Group 1 - Pollon Life, a Chinese stem cell therapy development company, has confidentially applied for an IPO in Hong Kong, aiming to raise approximately $300 million [1] - The company has received support from Jack Ma's Yunfeng Capital and is collaborating with Jianyin International, CICC, and UBS to advance its listing plans, with ongoing discussions that may adjust the IPO scale and details [1] - Pollon Life, formerly known as Platinum Biotech, developed China's first approved stem cell therapy, Aimi Maitosai injection, which is indicated for treating acute graft-versus-host disease in patients over 14 years old who have failed hormone therapy [1]